Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT). However, safety of AT is uncertain in these patients and the only data currently available derive from retrospective analyses of regi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Orphanet J Rare Dis
Auteurs principaux: Gaetani, Eleonora, Agostini, Fabiana, Porfidia, Angelo, Giarretta, Igor, Feliciani, Daniela, Di Martino, Luigi, Tortora, Annalisa, Gasbarrini, Antonio, Pola, Roberto
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Letter to the Editor
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6933630/
https://ncbi.nlm.nih.gov/pubmed/31878955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-019-1278-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires